Survival from methicillin-sensitive Staphylococcus aureus bloodstream infections over 20 years: a cohort of 1328 patients

Swiss Med Wkly. 2017 Sep 30:147:w14508. doi: 10.4414/smw.2017.14508. eCollection 2017.

Abstract

Purpose: Staphylococcus aureus bloodstream infections (SA BSI) are associated with substantial mortality. The rapid emergence of methicillin-resistant S. aureus (MRSA), known to be associated with worse outcome, may blur advances made regarding mortality attributed to SA BSI caused by methicillin-sensitive S. aureus (MSSA) strains. In the unusual setting of a very low MRSA prevalence institution, we investigated incidence, mortality and trends of BSI caused by MSSA over the last 20 years.

Objective: To evaluate and demonstrate trends in incidence and mortality of MSSA BSI as well as risk factors for mortality.

Methods: Retrospective, observational analysis of the prospective bloodstream infection cohort at the University Hospital Basel between January 1993 and December 2013. All patients with blood cultures positive for MSSA were included. All patients were analysed regarding pertinent demographic, clinical and antimicrobial treatment data. We calculated incidence, temporal trends and mortality of MSSA BSI.

Results: 1328 episodes of MSSA BSI were identified, accounting for a yearly incidence ranging from 2.1 to 4.5 per 10 000 patient-days (p = 0.2 for trend). Overall mortality was 19.3% and did not improve over time. Community-acquired MSSA BSI significantly increased over time, while nosocomial cases decreased (p <0.05).

Conclusions: Mortality related to MSSA BSI remains high and unchanged over the last 20 years. Despite advances in treatment and supportive care in medicine during the last 20 years survival did not improve and, therefore, new approaches are required to lower mortality in MSSA BSI.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Cross Infection / prevention & control
  • Hospital Mortality*
  • Hospitals
  • Humans
  • Methicillin-Resistant Staphylococcus aureus / pathogenicity
  • Prospective Studies
  • Risk Factors
  • Staphylococcal Infections / drug therapy*
  • Staphylococcal Infections / epidemiology*
  • Switzerland / epidemiology

Substances

  • Anti-Bacterial Agents